News & Events

Toft Group Completes Search for Vice President, Marketing for Exact Sciences Corp. (Nasdaq: EXAS) in Madison, WI

Executive search firm Toft Group has placed Kristen Weiler as Vice President of Marketing with Exact Sciences (Nasdaq: EXAS) in Madison, Wisconsin.

Ms. Weiler has held multiple roles in marketing across a broad range of therapeutic franchises. Her most recent position was as Senior Marketing Director of the Rheumatology portfolio at AbbVie, leading the brand performance of HUMIRA. Earlier in her industry career she led commercial development for ABT-874, anti-IL-12/23 antibody for psoriasis and Crohn’s disease and brand marketing for HUMIRA PsA indication in dermatology while also leading commercial development activities for future psoriasis indication. Ms. Weiler is actively involved in the Crohn’s and Colitis Foundation of America (CCFA) through fundraising and encouraging pediatric drug development.

Ms. Weiler holds a BS in Business Administration/Operations Management from the University of Wisconsin.

About Exact Sciences, Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

Toft Group Completes Search for Senior Medical Director for Leap Therapeutics (NASDAQ: LPTX) in Cambridge, MA

Executive search firm Toft Group has placed Girish Naik, MD, MBA as Senior Medical Director with Leap Therapeutics in Cambridge, MA.

Dr. Naik was previously a clinical researcher at Dana-Farber Cancer Institute. Before this appointment, Dr. Naik was Associate Scientific Manager/Medical Lead – Clinical Development at Biocon Research Ltd. where he was a physician-lead for novel biologics in oncology/immunology. Dr. Naik also served as PG Registrar (Pharmacology and Clinical Pharmacology) at Christian Medical College. He got his start in the medical industry as a surgeon at the M S Ramaiah Medical Teaching and Memorial Hospitals.

Dr. Naik holds an MD in Pharmacology from Christian Medical College in Vellore, India; an MBA from Sikkim Manipal University; and a diploma of advanced studies in pharmaceutical medicine from the University of Basel, Switzerland.

About Leap Therapeutics

Leap Therapeutics (NASDAQ:LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric cancer, biliary tract cancer, and gynecologic cancers, with an emerging focus on patients with defined mutations of the Wnt pathway and in combination with immune checkpoint inhibitors. Leap’s second clinical candidate, TRX518, is a novel, humanized GITR agonist monoclonal antibody designed to enhance the immune system’s anti-tumor response that is in two advanced solid tumor studies.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

Toft Group Completes Search for Vice President of Global Clinical Sciences for Greenwich Biosciences in Carlsbad, CA

Executive search firm Toft Group has placed Eduardo Dunayevich, MD, Vice-President of Global Clinical Sciences with Greenwich Biosciences in Carlsbad, CA.

Dr. Dunayevich is a board-certified psychiatrist with clinical development expertise within biotechnology and pharmaceutical companies. He recently served as Chief Medical Officer with Annexon Biosciences, with responsibility for clinical development, clinical operations and regulatory affairs across their neuroinflammation and intraocular therapy programs.

Previously, he held the role of Vice President and Global Product Lead, CNS at Takeda Pharmaceuticals. Prior to joining Takeda, Dr. Dunayevich was Executive Director and Global Development Leader, Neuroscience for Amgen. Dr. Dunayevich also spent 5 years with Orexigen Therapeutics as their Chief Medical Officer. Before that, he worked with Eli Lilly as a Medical Advisor in the Clinical Neuroscience Program Phase. Earlier in his industry career, Dr. Dunayevich served as Director of the Clinical Psychobiology Program, Psychobiology Inpatient Unit and Division of Clinical Trials of the Psychotic Disorders Research Program at the University of Cincinnati.
Dr. Dunayevich holds an MD from the University of Buenos Aires Medical School, Argentina.

About GW Pharmaceuticals plc and Greenwich Biosciences

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA approval for EPIDIOLEX (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older, pending DEA rescheduling. The Company has submitted a regulatory application in Europe for the adjunctive treatment of LGS and Dravet syndrome. The company continues to evaluate EPIDIOLEX in additional rare epilepsy conditions and currently has ongoing clinical trials in tuberous sclerosis complex (TSC) and infantile spasms (IS). GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a U.S. Phase 3 trial. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide. The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.